EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieKlinische Studie (Phase II)Open Access

Ceperognastat in Early Symptomatic Alzheimer Disease

Ceperognastat bei früher symptomatischer Alzheimer-Krankheit

Adam S Fleisher, Leanne Munsie, Michele Mancini, Yun-Ju Cheng, Jiaying Guo, Hugh Nuthall, Diana Svaldi Otero, Vikas Kotari, William Kielbasa, Michael Hutton, Miroslaw Brys, Dustin J Mergott und 2 weitere

JAMA · 22.09.2026 · 336 (12) · 1017

DOI: 10.1001/jama.2026.12768 ↗

Auf einen Blick

In einer Phase-2-Studie mit 327 randomisierten Personen zeigte Ceperognastat keinen klinisch bedeutsamen Nutzen gegenüber Placebo auf die Krankheitsprogression bei früher symptomatischer Alzheimer-Krankheit.

Fragestellung

Wirksamkeit und Sicherheit des oralen OGA-Inhibitors Ceperognastat bei früher symptomatischer Alzheimer-Krankheit

Methode

Doppelblinde, randomisierte, placebokontrollierte Phase-2-Studie an 72 Zentren in 5 Ländern; 1:1:1-Randomisierung; Beobachtung bis 100 Wochen.

Ergebnisse

327 randomisierte Teilnehmende; 259 in der primären Population. Keine klinisch relevante Wirkung auf iADRS. Krankheitsprogressionsratio vs. Placebo: 0,84 (95 %-KI 0,66–1,04) für 0,75 mg und 1,32 (95 %-KI 1,10–1,58) für 3 mg.

Schlussfolgerung der Autor:innen

Ceperognastat verlangsamte die Krankheitsprogression der frühen symptomatischen Alzheimer-Krankheit nicht.

Kernaussagen

  • Keine klinisch bedeutsame Wirkung auf iADRS
  • Progressionsratio vs. Placebo: 0,84 und 1,32
  • Mehr schwere und schwere unerwünschte Ereignisse unter 3 mg

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift JAMA, erschienen am 22.09.2026. Verfasst von Adam S Fleisher und 13 weiteren Autor:innen. Beteiligte Einrichtung: Eli Lilly and Company, Indianapolis, Indiana. Hauptthemen laut MEDLINE: Alzheimer Disease, Enzyme Inhibitors, N-Acetylglucosaminyltransferases. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Inhibiting O -linked N -acetylglucosaminidase (OGA) is hypothesized to slow accumulation of aggregated, hyperphosphorylated tau and neurofibrillary tangle formation.

Objective

To evaluate the efficacy and safety of the potent oral OGA inhibitor ceperognastat in early symptomatic Alzheimer disease (AD). Design, Setting, and Participants This double-blind, randomized, placebo-controlled phase 2 study was conducted at 72 sites in 5 countries from September 2021 to August 2024, with a posttreatment observational extension period through May 2025. The primary outcome population comprised participants with early symptomatic AD and biomarker evidence of tau pathology, including low to medium baseline tau levels (excluding individuals with high levels), as measured by positron emission tomography (PET) with flortaucipir F18.

Intervention

Participants were randomized 1:1:1 to receive once-daily, oral ceperognastat at doses of 0.75 mg (n = 110) or 3 mg (n = 108) or placebo (n = 108). Main Outcomes and Measures The primary outcome was change in Integrated AD Rating Scale (iADRS) score. The success criterion was a 60% or greater probability of achieving greater than or equal to 25% slower progression vs placebo using a bayesian probabilistic disease progression model. The 6 secondary outcomes were Alzheimer's Disease Assessment Scale–Cognitive Subscale, 13-item version; Alzheimer’s Disease Cooperative Study–Activities of Daily Living scale; Clinical Dementia Rating–Sum of Boxes; Mini-Mental State Examination; tau PET; and volumetric magnetic resonance imaging.

Results

Of the 327 randomized participants (mean age, 73.4 years; 201 [61.5%] females), 259 (87 receiving ceperognastat 0.75 mg, 86 receiving ceperognastat 3 mg, and 86 receiving placebo) with low to medium baseline tau levels were included in the primary outcome population (mean age, 74.3 years; 161 [62.2%] females). In this population, no clinically meaningful benefit vs placebo was observed for the primary end point (iADRS score) at 100 weeks: posterior mean change from baseline was −8.39 with ceperognastat 0.75 mg, −13.27 with ceperognastat 3 mg, and −10.07 with placebo. The disease progression ratio relative to placebo was 0.84 (95% credible interval [CrI], 0.66-1.04) for the ceperognastat 0.75 mg group and 1.32 (CrI, 1.10-1.58) for the ceperognastat 3 mg group, corresponding to 16% less and 32% greater progression, respectively. No benefits were demonstrated for secondary clinical end points. From baseline to 76 weeks, least-squares mean change in standardized uptake value ratio on PET showed a statistically significantly smaller increase ( P = .04) vs placebo only for the ceperognastat 3 mg group in the lateral temporal lobe. Volumetric magnetic resonance imaging showed less whole brain volume loss in participants treated with ceperognastat vs placebo (43.2% [ceperognastat 0.75 mg] and 49.5% [ceperognastat 3 mg] less vs placebo; both P < .001). The ceperognastat 3 mg group had more serious (ceperognastat 0.75 mg: n = 13 [12.0%]; ceperognastat 3 mg: n = 29 [26.4%]; placebo: n = 17 [15.7%]) and severe (ceperognastat 0.75 mg: n = 7 [6.5%]; ceperognastat 3 mg: n = 15 [13.6%]; placebo: n = 7 [6.5%]) treatment-emergent adverse events. Conclusions and Relevance Ceperognastat did not slow disease progression of early symptomatic AD. Trial Registration ClinicalTrials.gov Identifier: NCT05063539

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseEnzyme InhibitorsN-AcetylglucosaminyltransferasesAgedAged, 80 and overFemaleHumansMaleMiddle AgedAdministration, OralBiomarkersDisease ProgressionDouble-Blind MethodMinimal Clinically Important DifferencePositron-Emission Tomographytau ProteinsTreatment Outcome

Substanzen

BiomarkersEnzyme InhibitorsN-AcetylglucosaminyltransferasesO-GlcNAc transferasetau Proteins

Autor:innen und Institutionen

  • Eli Lilly and Company, Indianapolis, Indiana.

Zitieren

APA

Fleisher, A. S., Munsie, L., Mancini, M., Cheng, Y. J., Guo, J., Nuthall, H., Otero, D. S., Kotari, V., Kielbasa, W., Hutton, M., Brys, M., Mergott, D. J., Mintun, M., & Hansson, O. (2026). Ceperognastat in Early Symptomatic Alzheimer Disease. JAMA, 336(12), 1017. https://doi.org/10.1001/jama.2026.12768

Vancouver

Fleisher AS, Munsie L, Mancini M, Cheng YJ, Guo J, Nuthall H, et al. Ceperognastat in Early Symptomatic Alzheimer Disease. JAMA. 2026;336(12):1017. doi:10.1001/jama.2026.12768

BibTeX
@article{Fleisher2026,
  author = {Fleisher, Adam S and Munsie, Leanne and Mancini, Michele and Cheng, Yun-Ju and Guo, Jiaying and Nuthall, Hugh and Otero, Diana Svaldi and Kotari, Vikas and Kielbasa, William and Hutton, Michael and Brys, Miroslaw and Mergott, Dustin J and Mintun, Mark and Hansson, Oskar},
  title = {Ceperognastat in Early Symptomatic Alzheimer Disease},
  journal = {JAMA},
  year = {2026},
  volume = {336},
  number = {12},
  pages = {1017},
  doi = {10.1001/jama.2026.12768}
}
Kostenlos starten →